Accession Number : AD1032760

Title :   Targeting Androgen Receptor in Breast Cancer: Enzalutamide as a Novel Breast Cancer Therapeutic

Descriptive Note : Technical Report,15 Aug 2015,14 Aug 2016

Corporate Author : University of Colorado, Anschutz Medical Campu Aurora United States

Personal Author(s) : Richer,Jennifer K

Full Text :

Report Date : 01 Sep 2016

Pagination or Media Count : 130

Abstract : In breast cancers, the androgen receptor (AR) is more widely expressed than estrogen receptor alpha (ER) or the progesterone receptor (PR) (1), which are used as therapeutic targets and biomarkers, suggesting a potential role for AR in BC. To explore the function of AR in models of the three main subtypes of breast cancer (ER positive, ER negative and Her2 ), we are using anew-generation AR inhibitor, enzalutamide, which impairs nuclear localization of AR. This is a very different mode of action than previous generation anti-androgens such as bicalutamide (Casodex), which is a competitive inhibitor of endogenous androgens that allows ligand-mediated nuclear localization of AR. Enzalutamide has shown success in the clinic in patients with late stage prostate cancer. The research in this proposal generates preclinical data testing whether inhibition of AR with enzalutamide will be effective in breast cancer and utilize preclinical models of the three main subtypes of breast cancer. Our goal is to determine if and how enzalutamide should be combined with currently used standard of care treatments in the three main types of breast cancer, with the primary objectives of the research being to guide the design of future clinical trials with enzalutamide.

Descriptors :   breast cancer , carcinoma , proteomics , oncology , statistical analysis , cell physiological processes , proteins , biological factors , chemotherapy , clinical trials , experimental design , neoplasms , epithelial cells , receptor sites (physiology) , growth factors , resistance (biology) , ENDOCRINE GLANDS , inhibitors

Subject Categories : Medicine and Medical Research

Distribution Statement : APPROVED FOR PUBLIC RELEASE